






































 CURRENTOPINION Multimodal imaging of thyroid cancer
Katrin Brauckhoffa,b and Martin Biermannc,d
Purpose of review
Thyroid cancer is the most common endocrine cancer in adults with rising incidence. Challenges in
imaging thyroid cancer are twofold: distinguishing thyroid cancer from benign thyroid nodules, which
occur in 50% of the population over 50 years; and correct staging of thyroid cancer to facilitate
appropriate radical surgery in a single session. The clinical management of thyroid cancer patients has
been covered in detail by the 2015 guidelines of the American Thyroid Association (ATA). The purpose of
this review is to state the principles underlying optimal multimodal imaging of thyroid cancer and aid
clinicians in avoiding important pitfalls.
Recent findings
Recent additions to the literature include assessment of ultrasound-based scoring systems to improve
selection of nodules for fine needle biopsy (FNB) and the evaluation of new radioactive tracers for imaging
thyroid cancer.
Summary
The mainstay of diagnosing thyroid cancer is thyroid ultrasound with ultrasound-guided FNB. Contrast-
enhanced computed tomography and PET with [18F]-fluorodeoxyglucose (FDG) and MRI are reserved for
advanced and/or recurrent cases of differentiated thyroid cancer and anaplastic thyroid cancer, while
[18F]FDOPA and [68Ga]DOTATOC are the preferred tracers for medullary thyroid cancer.
Keywords
adult, follicular, medullary, papillary, thyroid cancer, thyroid nodule
INTRODUCTION
The greatest challenge in imaging thyroid cancer is
distinguishing thyroid cancer from benign disease
in the thyroid gland. Although thyroid cancer rep-
resents the most common endocrine malignancy in
adults [1], it is still rare compared with benign
thyroid nodules, which are seen on high-resolution
ultrasound in more than 30% of men and 50% of
women over 50 years [2]. The prevalence of thyroid
cancer in typical patient cohorts may range from 1%
in a general practice/radiology setting to 10% or
higher in a specialist clinic [3], depending to a large
extent on the referral pattern and the type of insti-
tution. When a patient presents with symptoms
such as a palpable lateral neck mass or hoarseness,
or has a genetic syndrome, the likelihood for malig-
nancy is markedly increased. The clinical manage-
ment of patients suspected for thyroid cancer is
described in detail in the current guidelines of the
American Thyroid Association (ATA) [4].
The present review will focus on imaging of the
four common cancer types in the thyroid gland:
papillary (PTC), follicular (FTC), poorly differenti-
ated (PDTC) and anaplastic (ATC), as well as medul-
lary (MTC) (Table 1) [5–7,8
&
,9–11]. PTC and FTC are
both derived from the follicular epithelium. They
share the ability to take up iodine due the expression
of sodium-iodide-symporter (NIS) and are often
grouped together as differentiated thyroid cancer
(DTC) [4,12]. Generally, thyroid cancer imaging is
performed in three different scenarios: primary
detection and initial staging of thyroid cancer, to
monitor therapy after surgery and to diagnose
suspected recurrence.
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REVIEW
IMAGING OF DIFFERENTIATED THYROID
CANCER: PRIMARY DETECTION AND
STAGING
Primary imaging for DTC serves to establish the
diagnosis of DTC, exclude malignancy in the con-
tralateral thyroid lobe if hemithyroidectomy is con-
sidered, detect local invasion, and identify and map
lymph node metastases to the lateral neck.
The mainstay for primary diagnosis thyroid can-
cer is high-resolution ultrasound of the thyroid
gland including ultrasound-guided fine needle
biopsy (FNB) of any suspect thyroid nodules [4].
Five criteria on brightness-mode (B-mode) ultra-
sound help identify malignancy in thyroid nodules:
solidity, hypoechogenecity, taller than wide shape
(anterior-posterior diameter larger than width in an
axial scan; N. B. 92% of isthmic PTC are wider than
tall [13]), irregular margin, and macro- and micro-
calcification [14,15]. Note that follicular neoplasms
including FTC often have a different appearance as a
solitary, well defined, solid, homogeneous, isoe-
choic or hypoechoic nodule, with a peripheral halo,




The major new advance in recent years has been
the development of easy to use classification sys-
tems for thyroid nodules on thyroid ultrasound. The
following dominate: The classifications proposed by
the ATA [4] and American Association of Clinical
Endocrinologists (AACE) [17], and the Thyroid
Imaging Reporting and Data Systems (TIRADS)
released by the Korean Society of Thyroid Radiology
(K-TIRADS) [18], the European Thyroid Association
(EU-TIRADS) [14] and the American College of Radi-
ology (ACR-TIRADS) [15,19
&
]. In a recent meta-anal-
ysis comparing the performance of the three
TIRADS, categories 4 and 5 had a sensitivity of about
90% for the detection of DTC with specificities
between 50 and 60% [20]. In a recent prospective
study comparing five common systems side-by-side
with thyroid cytology as independent reference
standard, ACR-TIRADS was the most specific [20].
In our opinion, it is also the easiest to apply and
to teach.
Several other criteria of malignancy are not
included in the above systems. Capsular abutment
and loss of the hyperechogenic thyroid capsule may
indicate local invasion [21]. Hard texture on ultra-
sound elastography and central vessels on Doppler
ultrasound are rather machine-dependent [14,15].
Contrast-enhanced ultrasound, which is useful for
visualization of parathyroid glands [22], entails
additional costs for the contrast agent while it does
not obviate FNB.
None of the common TIRADS take into account
the functional state of a thyroid nodule. ATA and
AACE guidelines recommend performing thyroid
scintigraphy in addition to ultrasound in all patients
evaluated for thyroid nodules who have subnormal
serum thyrotropin (TSH) [4,17]. Hyperfunctioning
‘hot’ nodules are difficult to distinguish from hypo-
functioning ‘cold’ nodules based on ultrasound
alone (Fig. 1), and ultrasound classification systems
KEY POINTS
 Primary detection and staging of thyroid cancer relies
on thyroid ultrasound supplemented by ultrasound-
guided FNB. The various TIRADS help in selecting
which nodules to biopsy.
 The preoperative evaluation of advanced thyroid
cancer should include contrast-enhanced CT for
improved detection of regional lymph node metastases,
ideally supplemented by functional imaging on a
hybrid scanner in the same session.
 The preferred tracers are [18F]FDG for DTC and
[18F]FDOPA – when available – or [68Ga]DOTATOC
and analogues for MTC. Radioactive iodine isotopes
are used for therapy monitoring and imaging
recurrences in DTC.
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CEA, carcinoembryonic antigen; MEN, multiple endocrine neoplasia; met., metastases.
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will recommend FNB in at least 25% [23
&
,24,25]
even though hot nodules are nearly always benign
[26,27]. Reversely, focal uptake of [18F]fluorodeoxy-
glucose (FDG) on general oncology imaging [28] and
of [99mTc]MIBI on parathyroid imaging [29] indi-
cates thyroid malignancy (mostly PTC) in up to 30%
of cases. The prognostic relevance of coincidently
discovered secondary thyroid cancer is unclear
[30,31]. A recent study suggests that EU-TIRADS
may help avoid unnecessary FNB among FDG-posi-
tive nodules [32,33].
From a size of 10 mm and above, every suspicious
thyroid nodule should undergo ultrasound-guided
FNB [4]. Multinodular goiter does not appear to
increase of risk DTC per se [34]. A pragmatic approach
is to take FNB of the three most suspicious nodules
[14]. The optimal technique for FNB is hotly debated.
We prefer non-aspiration FNB, using three to four
needle passes under local anaesthesia [35,36].
ATA guidelines recommend the Bethesda clas-
sification for thyroid cytology (Table 2) [37–39].
FNB works best for PTC, which has a characteris-
tic appearance on cytology (Fig. 2). Cytological
diagnosis of FTC is impossible, as the differential
diagnosis of FTC versus follicular adenoma relies
on the detection of vascular and or/or capsular
invasion in a histological specimen. In both enti-
ties, cytology will only show varying degrees of
atypia [39]. Similarly, the diagnosis of follicular
thyroid neoplasm with papillary-like nuclear fea-
tures (NIFTP), a benign tumour, requires histopa-
thology [39]. Finally, the cytological appearance
of MTC is protean, and the follicular variant of
PTC may be difficult to differentiate from follic-
ular neoplasms [39].
Bethesda V and VI nodules will usually be
treated by surgery with the possible exception of
solitary PTC less than 10 mm in the absence of
FIGURE 1. A 71-year-old woman referred for thyroid ultrasound and FNB because of a thyroid nodule detected on computed
tomography. The patient’s serum TSH of 0.2 mU/ml had not been not considered in the referral. Thyroid ultrasound (a)
revealed a conglomerate of hypoechogenic nodules in the right thyroid lobe. ACR-TIRADS recommends FNB for this thyroid
nodule. Scintigraphy (b) showed that the nodules were toxic, obviating the need for FNB. The patient was treated with
radioiodine. FNB, fine needle biopsy. Adapted with permission from [25].
Table 2. Bethesda-system for thyroid cytology [39]
Category Designation Risk of malignancy Estimated frequency Recommended
I Nondiagnostic 5–10% 3% Repeat FNB
II Benign 0–3% 55% No follow-up
III Atypia 6–18% 7% Repeat FNB
IV Follicular neoplasm 10–40% 23% Repeat FNB & molecular testing
V suspicious 45–60% 6% Hemithyroidectomy
VI malignant 94–96% 5% Total thyroidectomy
Estimated frequencies are highly dependent on the referral practice, while the frequency of Bethesda I is strongly related to the dexterity of the US operator
[4,38].
FNB, fine needle biopsy.
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suspicious lymph nodes [40]. Categories Bethesda III
and IV are ‘cytologically indeterminate’. Bethesda
III nodules should primarily undergo repeat cytol-
ogy. The goal of category IV is to identify all poten-
tial follicular carcinomas, usually leading to
hemithyroidectomy. ATA guidelines recommend
molecular testing – when available – to rule in
and out malignancy [4]. When there is a possibility
for PTC, we routinely analyse samples for a somatic
BRAF mutation. When positive, this will establish
the diagnosis of PTC with more than 99%
specificity (rule-in test). Rule-out-testing to exclude
malignancy in Bethesda III and IV nodules is expen-
sive [41]. Functional imaging with [18F]FDG-PET
[42,43] and [99mTc]MIBI [44] will however have
similar diagnostic performance. Cytology is unreli-
able for the detection of MTC. In our institution, we
have chosen to screen all patients scheduled for
surgery for elevated serum calcitonin. Likewise,
cytology cannot be relied on to identify parathyroid
adenomas [45]. In patients under evaluation for
hyperparathyroidism, we therefore routinely ana-
lyse the washout from the FNB needle for parathy-
roid hormone [36,46].
FIGURE 2. A 34-year-old man presenting with a right lateral neck mass. Contrast-enhanced CT requested by the initially
consulted otorhinolaryngologist had revealed multiple lesions in the right lateral neck. Ultrasound at our centre showed a
10 mm hypoechoic nodule ‘A’ (a) in the right thyroid lobe and multiple cystic LN on both sides of the neck (b–e). FNB of
thyroid nodule ‘A’ (inset panel) and right cervical LN #8 (inset panel b) established the diagnosis of PTC. Thyroglobulin in the
aspirate from LN #8 was more than 2000 ng/l. [18F]FDG-PET/CT (f–i) revealed uptake only in thyroid nodule ‘A’ but not in
the cystic LN. CT without intravenous contrast (h) did not add any relevant diagnostic information. On PET/MR (panels J-L), all
cystic LN (arrows in panel l) were hyperintense on T2-weighted series. This helped us clarify the difficult anatomic relationships
around LN #12 (b). Total thyroidectomy with systematic LN dissection confirmed a 12 mm PTC in the right thyroid lobe and LN
metastases in 20/29 LN in the central, 4/12 in the right and 2/10 left neck, respectively. FNB, fine needle biopsy; LN,
lymph node.
Thyroid
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Cervical ultrasound for thyroid disease should
always include screening for suspicious regional LN.
The following three signs in B-mode ultrasound
increase the likelihood of malignancy: round shape,
hypoechogenicity, loss of hilar echo [47,48]. Cystic
lymph nodes are almost pathognomonic of PTC
(Fig. 2) but may also occur in squamous cell cancer.
The hallmark of a malignant lymph node is focal
hyperperfusion on Doppler ultrasound (Fig. 3a)
[48,49].
Whenthyroidcancer is established based onFNB,
we routinely perform a second ultrasound examina-
tion to specifically exclude lymph node metastases in
the lateral neck, both ipsilateral and contralateral,
with particular attention to lymph nodes at the
edges of lymph node dissection regions. In
addition to B-mode, every lymph node is examined
with high-resolution Doppler (Fig. 3). In case of
suspicious lymph nodes, we perform ultrasound-
guided FNB of one lymph node per lateral cervical
compartment. The technique is similar to FNB of
thyroid lesions. However, cytology may only reveal
lymphatic cells or fluid with macrophages in case of
cystic lymph nodes. We therefore routinely supple-
ment cytology with biochemistry: thyroglobulin in
case ofDTC, calcitonin in case ofMTC[36,49]. Rarely,
lymph node metastases can occur with a very small or
no detectable primary in the thyroid gland [50]. In
these cases, detection of malignancy rests on lymph
node biopsy. Imaging of lymph nodes in the central
compartment (level IV) is challenging to perform
with ultrasound [51] but has limited relevance in
institutions in which central lymph node dissection
is part of the surgical routine.
FIGURE 3. A 51-year-old man with medullary thyroid cancer pT1a (4 mm) pN1. Total thyroidectomy with left lateral LN
dissection in 2003. In 2011, [18F]FDG-PET including CT-CT showed two enhancing but FDG-negative LN metastases, which
were confirmed on surgery. Rising serum calcitonin (25.1 pmol/l). Ultrasound in October 2019 showed a 5 mm hyperperfused
LN (a). FNB revealed malignant cells (a), calcitonin from the aspirate was 3850 pmol/l. [18F]FDOPA-PET in Aarhus/Denmark
(c–f) revealed two foci: the known LN metastasis and a focus in the left central neck. Subsequent [68Ga]DOTATOC-PET with a
dedicated CE-CT of the neck with arms down (g–j) at our center confirmed both foci and allowed us to localize the central
cervical lesion by US (b). The prevertebral focus (arrow in j) is physiological tracer uptake in the right stellate ganglion. CE-CT,
contrast-enhanced CT; FNB, fine needle biopsy; LN, lymph node.
Thyroid cancer imaging Brauckhoff and Biermann
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Variations in vascular anatomy need to be
recorded. We routinely document the common ori-
gin of right subclavian and carotid arteries from the
innominate artery, as a subclavian artery originating
directly from the aortic isthmus and passing behind
the trachea (lusorian artery) is associated with a
nonrecurrent inferior laryngeal nerve with major
implications for surgical management [52].
In case of locally and regionally advanced dis-
ease, guidelines recommend computed tomography
(CT) [4]. We prefer contrast-enhanced CT (CE-CT)
for improved delineation of vascular anatomy and
for the detection of regional lymph node metastases,
especially in cases with MTC. The role of preopera-
tive [18F]FDG PET/CT in addition to CE-CT is at
present not firmly established [53–55]. However,
we routinely perform [18F]FDG PET with coregis-
tered CE-CT of neck and mediastinum down to
the tracheal bifurcation. Since 2019, we also include
PET/MR [56] for a better delineation the central
viscera and of cystic lymph nodes (Fig. 2).
Error-free communication between endocrine
surgeon and imaging specialist is paramount. We
routinely summarize the findings in a hand drawing
of all pertinent imaging findings in relation to the
patient’s vascular anatomy [57]. The drawings are
scanned in and stored alongside the ultrasound
images in the Picture Archival and Communications
System and follow the patient into the operating
theatre (Fig. 2).
IMAGING OF DIFFERENTIATED THYROID
CANCER: THERAPY MONITORING
DTC expresses NIS. It has therefore the ability to take
up radioactive iodine, at least under conditions of
TSH stimulation, either endogenous (4 weeks’ with-
drawal of levothyroxine leading to a TSH >30 mU/l)
or by intramuscular injection of recombinant
human TSH (rhTSH) [4]. Three radioactive isotopes
can be used: 131I (physical half-life 8 days), which
emits both gamma radiation, which is needed for
conventional nuclear medicine imaging, and beta
radiation, which irradiates the surrounding tissue
with a maximum range of approx. 2 mm; 123I (13 h),
a gamma emitter; and 124I (4 days), a positron emit-
ter [58,59].
Until the turn of the millennium, many insti-
tutions routinely applied 131I to ablate thyroid rem-
nant tissue after total thyroidectomy apart from
using it to treat regional or distant iodine-avid
metastases [60]. Thyroid ablation has come under
increasing scrutiny, at least for patients with low-
risk thyroid cancer [4,61
&&
,62–64]. Following abla-
tion, the distribution of radioactivity is documented
by planar whole-body scintigraphy, and – ideally –
three-dimensional conventional imaging using sin-
gle photon emission computed tomography
(SPECT) in combination with CT [65].
Three aspects are important. First, we routinely
perform cervical ultrasound in conjunction with
SPECT/CT to detect regional lymph node metastases
that were overlooked on preoperative staging. Small
iodine-avid lymph node metastases can be followed
up with ultrasound, as 131I may be curative, while
iodine-negative lymph node metastases require
repeat surgery [66]. Second, SPECT/CT helps to iden-
tify iodine avid accessory thyroid tissue such a pyra-
midal lobe that may otherwise be mistaken for
thyroid remnants [65]. Third, Post therapeutic 131I
scintigraphy can be the only imaging modality to
detect – and treat – miliary pulmonary metastases
in PTC, as the lung lesions are too small to be picked
up by routine chest CT [67].
After ablation, routine imaging consists of peri-
odic cervical ultrasound. Two retrospective series
suggest that a follow-up regime including ultra-
sound performed 4 weeks, 1 year and 5 years after
initial surgical therapy will detect about 90% of
recurrences in low-risk DTC [68–70].
IMAGING OF DIFFERENTIATED THYROID
CANCER: RECURRENCE
Distinguishing true recurrence from persisting dis-
ease that was overlooked on primary therapy can
be difficult [57,71
&&
]. Recurrence of DTC is sus-
pected when a patient detects a new painless lump
in the neck, when there is a rise of serum thyro-
globulin (Tg), and in case of persisting high levels
of anti-thyro-globulin antibodies [4].
Initial imaging should include ultrasound of the
neck including ultrasound-guided FNB of suspicious
lesions [4,49]. Reactive lymph node at the edge of a
previous systematic lymph node dissection may be
difficult to distinguish from metastases, as they
often are hypoechoic and enlarged with an abnor-
mal shape. Doppler-ultrasound may help, but the
definitive diagnosis often rests on FNB with deter-
mination of Tg in the washout from the biopsy
needle [49].
Functional imaging of DTC has two compo-
nents: demonstrating iodine avid disease that can
be treated with high-dose 131I, and demonstrating
cancer tissue that has lost the ability to concentrate
iodine and that needs to be treated by surgery or
external beam therapy [12].
Imaging for iodine avid disease is performed
under TSH stimulation using 123I or 131I whole-body
scintigraphy, ideally supplemented by SPECT/CT of
neck and mediastinum to both increase sensitivity
and improve localization [4]. 124I PET is the most
Thyroid
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sensitive method for the detection or characteriza-
tion of small lesions [72]. For pretherapeutic dosim-
etry, a small activity of 124I, typically 37–74 MBq, is
injected or ingested. Images are taken 48 h, and if
positive, 96 h later [58]. Post therapeutic planar
scintigraphy 72–96 h after the application at least
3000 MBq 131I is still the most sensitive method for
the detection of miliary pulmonary metastases in
PTC [67], for which high-dose 131I therapy is cura-
tive [73].
The mainstay for imaging recurrent DTC includ-
ing iodine-refractory disease is [18F]FDG PET [74].
When DTC de-differentiates, DTC may fail to
express NIS, and glucose uptake is upregulated. An
important caveat is that glucose uptake is also upre-
gulated in inflammatory foci, which often leads to
false positive findings in cervical lymph nodes [49].
Patient-based pooled sensitivity and specificity of
[18F]FDG for the detection of recurrent DTC are both
80% [74]. However, these estimates are probably
overoptimistic, as diagnostic studies often lack a
reference standard that is truly independent of
imaging and/or sufficient follow-up [74]. In our
own series of 51 patients imaged for suspected recur-
rent DTC from 2009 to 2014, lesion-based sensitivity
of [18F]FDG PET was 85% and specificity was 70%.
Post-PET ultrasound including ultrasound-guided
FNB of all suspicious lesions increased specificity
to 90% while maintaining sensitivity [49]. TSH stim-
ulation increases lesional uptake of [18F]FDG [75],
but it may no longer be needed due to the improved
sensitivity of the most recent generation of
PET scanners.
[68Ga]DOTATOC has been used for DTC imaging
[76,77] but without convincing evidence that it is
superior to [18F]FDG. Two recent case series show that
ligands to prostate-specific membrane antigen
(PSMA) may show focal uptake in patients with rising
serum Tg, negative 131I scintigraphy and [18F]FDG-
PET [78,79]. However, unspecific foci especially in
the thorax are frequently encountered on imaging
with [18F]PSMA-1007, which has a higher resolution
than the 68Ga-labeled PSMA ligands [80]. PSMA PET
for thyroid cancer therefore needs confirmation in
larger series with a firm diagnostic standard that is
independent of imaging, ideally cytology or histol-
ogy. 68Ga-labelled fibroblast activation protein inhib-
itor (FAPI) is an oligopeptide that has moderate
uptake in thyroid cancer [81]. The tracer excels in
imaging pancreatic cancer, as it is cancer-specific
without uptake in inflammatory lesions [81].
Another new PET tracer, [18F]tetrafluoroborate
(TFB) is taken up by NIS [82
&&
]. In a recent study in
25 patients with suspected DTC, [18F]TFB-PET
showedfocal uptake in recurrent tumor in13 patients
while 131I SPECT-CT was positive only in 3 [82
&&
].
IMAGING OF MEDULLARY THYROID
CANCER
The primary diagnosis of MTC follows the same
principles as for DTC with two caveats: cytology is
unreliable; micrometastases to cervical lymph node
are common, and macrometastases to lymph node
may be discontinuous and often contralateral [9].
Unlike DTC, MTC does not express NIS, and there-
fore has no iodine uptake. Three tracers are first
choice for imaging MTC: [18F]FDOPA, [68Ga]DOTA-
TOC (and analogues) and [18F]FDG [83,84,85
&
]. The
latter is least sensitive, but useful with increasing de-
differentiation, particularly when S-CEA rises more
rapidly than S-calcitonin [85
&
]. Only one study com-
pared the three tracers in the same patients [86]. The
most sensitive tracer for well differentiated MTC is
[18F]FDOPA [87
&
,88]. However, it is available only at
very few select institutions. [68Ga]DOTATOC, an
increasingly ubiquitous tracer for neuroendocrine
tumours, is not quite as sensitive, but more so than
[18F]FDG [85
&
]. Note that [68Ga]DOTATOC may
show physiological uptake in the stellate ganglia
(Fig. 3 h.j) [89]. Other tracers that have been used
for imaging MTC include radioactively labelled gas-
trin analogues [90], but there are at present no series
that document the superiority of these new tracers
over [18F]FDOPA.
We use [68Ga]DOTATOC rather than [18F]FDG
for staging before primary surgery, while we are
eagerly awaiting the forthcoming production of
[18F]FDOPA in our own cyclotron unit. For stag-
ing-suspected recurrent disease, we routinely com-
plement ultrasound and FNB at our own institution
with [18F]FDOPA with coregistered CE-CT of neck
and mediastinum at a cooperating center abroad
(Fig. 3).
IMAGING OF ANAPLASTIC THYROID
CANCER
ATC is one of the most aggressive human cancers.
Still, up to 20% of patients experience lasting cure
after radical surgery in combination with radio-
chemotherapy if cancer is limited to the thyroid
gland and regional lymph nodes [91,92]. The main
differential diagnosis is thyroid lymphoma, which
is primarily treated with chemotherapy, often in
combination with radiation. [18F]FDG is the PET
imaging agent of choice for both [93,94]. In case of
ATC, we routinely perform [18F]FDG PET/CT with
CE-CT and PET/MR of neck and mediastinum,
supplemented by core-needle biopsy (CNB) of
the primary tumour for histological confirmation
before surgery. In addition to CNB, we aspirate
cells from the tumour and perform flow cytometry
to exclude lymphoma [95]. MRI and endoscopy
Thyroid cancer imaging Brauckhoff and Biermann
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are important to establish intactness of the
central viscera.
CONCLUSION
The mainstay of thyroid cancer imaging is cervical
ultrasound in combination with ultrasound-guided
FNB. Thyroid scintigraphy with [99mTc]pertechne-
tate is used in patients with suppressed TSH for the
detection of toxic nodules, which are nearly always
benign. Imaging methods for DTC are scintigraphy
with radioactive iodine isotopes and [18F]FDG-PET.
Recommended imaging methods for MTC are
[18F]FDOPA (when available), [68Ga]DOTATOC
and [18F]FDG-PET.
Acknowledgements
We thank Hans Kristian Haugland, PhD, from the
Department of Pathology at Haukeland University Hos-
pital for the cytology images and valuable advice regard-
ing cytology, and Lars Rokne Reisæter, MD, from the
Department of Radiology for helpful review of our man-
uscript.
Financial support and sponsorship
None.
Conflicts of interest
M. B. is an advisor (unpaid) for Segami Corp., Inc.,
Columbus/MD.
This manuscript has not been submitted elsewhere.
REFERENCES AND RECOMMENDED
READING
Papers of particular interest, published within the annual period of review, have
been highlighted as:
& of special interest
&& of outstanding interest
1. Olson E, Wintheiser G, Wolfe KM, et al. Epidemiology of thyroid cancer: a
review of the National Cancer Database. Cureus 2019; 11:e4127.
2. Moon JH, Hyun MK, Lee JY, et al. Prevalence of thyroid nodules and their
associated clinical parameters: a large-scale, multicenter-based health check-
up study. Korean J Intern Med 2018; 33:753–762.
3. Ha SM, Baek JH, Choi YJ, et al. Malignancy risk of initially benign thyroid
nodules: validation with various Thyroid Imaging Reporting and Data System
guidelines. Eur Radiol 2019; 29:133–140.
4. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Associa-
tion Management guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: the American Thyroid Association Guidelines
Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid
2016; 26:1–133.
5. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review
1975-2017. Bethesda/MD: National Cancer Institute. https://seer.cancer.-
gov/csr/1975_2017 (accessed May 17, 2020).
6. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Survival and long-term
biochemical cure in medullary thyroid carcinoma in Denmark 1997-2014: a
nationwide study. Thyroid 2019; 29:368–377.
7. Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involve-
ment on survival in patients with papillary and follicular thyroid carcinoma.
Surgery 2008; 144:1070–1077discussion 1077–1078.
8.
&
Grani G, Lamartina L, Durante C, et al. Follicular thyroid cancer and H€urthle
cell carcinoma: challenges in diagnosis, treatment, and clinical management.
Lancet Diabetes Endocrinol 2018; 6:500–514.
An in-depth review of follicular and oncocytic (H€urthle cell) thyroid cancer.
9. Machens A, Dralle H. Prognostic impact of N staging in 715 medullary thyroid
cancer patients: proposal for a revised staging system. Ann Surg 2013;
257:323–329.
10. Iyer NG, Shaha AR. Management of thyroid nodules and surgery for differ-
entiated thyroid cancer. Clin Oncol (R Coll Radiol) 2010; 22:405–412.
11. Paschke R, Lincke T, M€uller SP, et al. The treatment of well differentiated
thyroid carcinoma. Dtsch Arztebl Int 2015; 112:452–458.
12. Van Nostrand D. Radioiodine refractory differentiated thyroid cancer: time to
update the classifications. Thyroid 2018; 28:1083–1093.
13. Hahn SY, Han B-K, Ko EY, et al. Ultrasound findings of papillary thyroid
carcinoma originating in the isthmus: comparison with lobe-originating papil-
lary thyroid carcinoma. AJR Am J Roentgenol 2014; 203:637–642.
14. Russ G, Bonnema SJ, Erdogan MF, et al. European Thyroid Association
Guidelines for ultrasound malignancy risk stratification of thyroid nodules in
adults: the EU-TIRADS. Eur Thyroid J 2017; 6:225–237.
15. Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting
and Data System (TI-RADS): white paper of the ACR TI-RADS Committee. J
Am Coll Radiol 2017; 14:587–595.
16. Kobayashi K, Hirokawa M, Yabuta T, et al. Tumor protrusion with intensive
blood signals on ultrasonography is a strongly suggestive finding of follicular
thyroid carcinoma. Med Ultrason 2016; 18:25–29.
17. Gharib H, Papini E, Garber JR, et al. American Association of Clinical
Endocrinologists, American College of Endocrinology, and Associazione
Medici Endocrinologi Medical guidelines for clinical practice for the diagnosis
and management of thyroid nodules – 2016 update. Endocr Pract 2016;
22:622–639.
18. Shin JH, Baek JH, Chung J, et al. Ultrasonography diagnosis and imaging-
based management of thyroid nodules: revised Korean Society of Thyroid




Tessler FN, Middleton WD, Grant EG. Thyroid Imaging Reporting and Data
System (TI-RADS): a user’s guide. Radiology 2018; 287:29–36.
This pictorial guide explains how to use ACR-TIRADS to assess the need for FNB
in thyroid nodules.
20. Grani G, Lamartina L, Ascoli V, et al. Reducing the number of unnecessary
thyroid biopsies while improving diagnostic accuracy: toward the ‘right’
TIRADS. J Clin Endocrinol Metab 2019; 104:95–102.
21. Kamaya A, Tahvildari AM, Patel BN, et al. Sonographic detection of extra-
capsular extension in papillary thyroid cancer. J Ultrasound Med 2015;
34:2225–2230.
22. Agha A, Hornung M, Stroszczynski C, et al. Highly efficient localization of
pathological glands in primary hyperparathyroidism using contrast-enhanced
ultrasonography (CEUS) in comparison with conventional ultrasonography. J
Clin Endocrinol Metab 2013; 98:2019–2025.
23.
&
Noto B, Eveslage M, Pixberg M, et al. Prevalence of hyperfunctioning thyroid
nodules among those in need of fine needle aspiration cytology according to
ATA 2015, EU-TIRADS, and ACR-TIRADS. Eur J Nucl Med Mol Imaging
2020; 47:1518–1526.
In a series of 566 patients with serum TSH in the normal range, the prevalence of
hyperfunctioning nodules in thyroid scintigraphy was 8%. There were no criteria on
B-mode US that allowed the identification of toxic nodules, while three of the most
commonly used US classification systems spuriously recommended FNB in 25–
50% of hyperfunctioning nodules.
24. Schenke S, Seifert P, Zimny M, et al. Risk stratification of thyroid nodules
using the Thyroid Imaging Reporting and Data System (TIRADS): the omis-
sion of thyroid scintigraphy increases the rate of falsely suspected lesions. J
Nucl Med 2019; 60:342–347.
25. Biermann M. Ultrasound classification systems estimating thyroid malignancy
fail to recognize hyperfunctional nodules. Clin Thyroidol 2020; 32:225–228.
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